Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect
Regional lymph node status is one of the important prognostic indicators of breast cancer, which can guide the staging and adjuvant treatment strategy. Sentinel lymph node biopsy (SLNB) for breast cancer has developed rapidly over the past three decades, evidence-based medicine class Ⅰ e...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2022-08-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1663559405639-1497812931.pdf |
| _version_ | 1798031845036654592 |
|---|---|
| author | QIU Pengfei, WANG Yongsheng |
| author_facet | QIU Pengfei, WANG Yongsheng |
| author_sort | QIU Pengfei, WANG Yongsheng |
| collection | DOAJ |
| description | Regional lymph node status is one of the important prognostic indicators of breast cancer, which can guide the staging and adjuvant treatment strategy. Sentinel lymph node biopsy (SLNB) for breast cancer has developed rapidly over the past three decades, evidence-based medicine class Ⅰ evidence supports that SLNB is a safe and effective axillary staging technique for patients with clinically negative axillary lymph node in early breast cancer. The risk of axillary recurrence and complications in breast cancer patients with negative/few-positive sentinel lymph node omitting axillary lymph node dissection is very low. Locoregional management of breast cancer should consider the metastatic risk of the primary tumor, the efficacy and side effects of systemic therapy, and the efficacy and side effects of locoregional therapy (surgery/radiotherapy). This view has promoted the continuous expansion of the SLNB population. SLNB with neoadjuvant therapy and internal mammary SLNB will further promote the de-escalation therapy, and the ongoing studies of omission of axillary surgery should be anticipated. The era of precision medicine for regional lymph node management of breast cancer has gradually arrived with the development of SLNB. This article evaluated the latest progress of precise regional processing of breast cancer in the sentinel lymph node era, in order to provide reference for clinical doctors. |
| first_indexed | 2024-04-11T20:03:03Z |
| format | Article |
| id | doaj.art-f1d22243869e493aaf7b89d673ce9103 |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-04-11T20:03:03Z |
| publishDate | 2022-08-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-f1d22243869e493aaf7b89d673ce91032022-12-22T04:05:31ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392022-08-0132868068710.19401/j.cnki.1007-3639.2022.08.002Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospectQIU Pengfei, WANG Yongsheng0Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong Province, ChinaRegional lymph node status is one of the important prognostic indicators of breast cancer, which can guide the staging and adjuvant treatment strategy. Sentinel lymph node biopsy (SLNB) for breast cancer has developed rapidly over the past three decades, evidence-based medicine class Ⅰ evidence supports that SLNB is a safe and effective axillary staging technique for patients with clinically negative axillary lymph node in early breast cancer. The risk of axillary recurrence and complications in breast cancer patients with negative/few-positive sentinel lymph node omitting axillary lymph node dissection is very low. Locoregional management of breast cancer should consider the metastatic risk of the primary tumor, the efficacy and side effects of systemic therapy, and the efficacy and side effects of locoregional therapy (surgery/radiotherapy). This view has promoted the continuous expansion of the SLNB population. SLNB with neoadjuvant therapy and internal mammary SLNB will further promote the de-escalation therapy, and the ongoing studies of omission of axillary surgery should be anticipated. The era of precision medicine for regional lymph node management of breast cancer has gradually arrived with the development of SLNB. This article evaluated the latest progress of precise regional processing of breast cancer in the sentinel lymph node era, in order to provide reference for clinical doctors.http://www.china-oncology.com/fileup/1007-3639/PDF/1663559405639-1497812931.pdf|breast cancer|sentinel lymph node biopsy|axillary lymph node|internal mammary lymph node |
| spellingShingle | QIU Pengfei, WANG Yongsheng Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect Zhongguo aizheng zazhi |breast cancer|sentinel lymph node biopsy|axillary lymph node|internal mammary lymph node |
| title | Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect |
| title_full | Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect |
| title_fullStr | Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect |
| title_full_unstemmed | Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect |
| title_short | Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect |
| title_sort | precise regional management of breast cancer in the sentinel lymph node era evolution and prospect |
| topic | |breast cancer|sentinel lymph node biopsy|axillary lymph node|internal mammary lymph node |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1663559405639-1497812931.pdf |
| work_keys_str_mv | AT qiupengfeiwangyongsheng preciseregionalmanagementofbreastcancerinthesentinellymphnodeeraevolutionandprospect |